Back to Journals » Clinical Interventions in Aging » Volume 8

Anemia associated with chronic heart failure: current concepts

Authors Shah R, Agarwal A

Received 12 September 2012

Accepted for publication 10 November 2012

Published 4 February 2013 Volume 2013:8 Pages 111—122

DOI https://doi.org/10.2147/CIA.S27105

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Video abstract presented by Ravish Shah and Anil K Agarwal

Views: 3025

Ravish Shah, Anil K Agarwal

Division of Nephrology, The Ohio State University, Columbus, Ohio, USA

Abstract: Anemia is a frequent comorbidity of heart failure and is associated with poor outcomes. Anemia in heart failure is considered to develop due to a complex interaction of iron deficiency, kidney disease, and cytokine production, although micronutrient insufficiency and blood loss may contribute. Currently, treatment of anemia of heart failure lacks clear targets and specific therapy is not defined. Intravenous iron use has been shown to benefit anemic as well as nonanemic patients with heart failure. Treatment with erythropoietin-stimulating agents has been considered alone or in combination with iron, but robust evidence to dictate clear guidelines is not currently available. Available and emerging new agents in the treatment of anemia of heart failure will need to be tested in randomized, controlled studies.

Keywords: anemia, heart failure, chronic kidney disease, elderly population

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.